PJPInvesco Pharmaceuticals ETF
Tracks the investment results of the Dynamic Pharmaceutical Intellidex Index.
By Invesco · Launched 2005
Annual Cost
0.58%
#3,147 of 6,040 · average
Fund Size
$532M
#1,608 of 6,040 · large
Return (1Y)
+40.1%
Track Record
21 years
#233 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$13,463+34.6%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
Dynamic Pharmaceutical Intellidex Index
Holdings
By weightConcentration
Top 10 holdings = 54.9% of fundmoderately concentrated
Invesco Private Prime Fund
12.1%
Pfizer Inc.
5.2%
Johnson & Johnson
4.9%
AbbVie Inc.
4.9%
Amgen Inc.
4.8%
Eli Lilly and Co.
4.8%
Gilead Sciences, Inc.
4.7%
Merck & Co., Inc.
4.7%
Invesco Private Government Fund
4.6%
Abbott Laboratories
4.2%
Asset allocation
Stocks
100.0%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
17.0%Moderate
Year-on-year price swings
Max drawdown
-33.9%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.92Decent risk-adjusted returns
Sortino (3Y)
1.32Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Tracks the investment results of the Dynamic Pharmaceutical Intellidex Index.
- Strategy
- Invests at least 90% of total assets in common stocks of U.S. pharmaceutical companies, employing full replication to track the Dynamic Pharmaceutical Intellidex Index. Concentrates investments in the pharmaceutical and biotechnology industries, reflecting the Underlying Index's composition.
- Inception date
- June 23, 2005
- Fund family
- Invesco
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save PJP to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18